HotCopper's Week 30 highlights focused on the stocks that drew the most views and discussion across the Australian stock forum over the past week, led by American Tungsten, PolyNovo, Anson Resources, Liontown Resources, Mesoblast and Racura Oncology.

American Tungsten ranked at the top of the most viewed list as forum users continued to track the company's efforts to position itself as a key U.S. supplier of tungsten and antimony. Both minerals are classified as critical minerals by the U.S. government and are seeing increased demand from the defence sector, where tungsten is used in armour-piercing munitions and antimony in explosives and flame retardants. China dominates global supply of both materials and has tightened antimony export controls, adding to the strategic case for Western-aligned suppliers.

The company entered a trading halt today ahead of what it described as a significant acquisition announcement. Interest in the stock has remained high following recent high-grade drilling results, a $10 million placement in June and the appointment of Casper Adson as chief executive officer.

PolyNovo was also among the most viewed stocks after coming under selling pressure during the week. The company reported FY26 group revenue of $150 million and positive free cash flow, while investors discussed whether the share-price weakness represented a buying opportunity. Attention remained on PolyNovo's NovoSorb wound care platform — a proprietary biodegradable polymer technology used in surgical and burn-dressings products sold across multiple international markets — and the company's longer-term growth outlook.

Anson Resources rounded out the most viewed names. The lithium developer stayed firmly on investors' radar after applying for additional mineral rights at its Green River Project in Utah, a move that would expand its mining footprint in a state that has attracted growing exploration interest as part of broader U.S. efforts to build a domestic battery-materials supply chain.

Anson was also one of the week's most discussed stocks. Forum users debated the potential implications of the expanded Green River footprint, the merits of the 17 new mineral blocks the company has applied for and upcoming project milestones in the U.S. lithium sector.

Liontown Resources generated strong discussion as traders continued to assess the outlook for lithium prices and the ramp-up at Kathleen Valley. Lithium spot prices have fallen sharply from their 2022 peaks amid concerns over global oversupply, and the Kathleen Valley operation in Western Australia is one of the larger new hard-rock lithium projects targeting first production. Battery metals remained one of the market themes most closely watched on the forum during the week.

Mesoblast remained a forum favourite after successfully treating 300 patients in a pivotal phase 3 clinical trial for a chronic lower back pain treatment. Traders discussed recent commercial progress for Ryoncil — Mesoblast's lead cell therapy candidate, which has navigated a prolonged regulatory review process with the U.S. FDA — and the advancement of the company's late-stage clinical pipeline, with conversation focused on future revenue growth and further regulatory milestones.

Racura Oncology was also among the most discussed stocks after it was revealed that the first cohort in a major chemotherapy trial proceeded safely with no dose-limiting toxicity. The company is scheduled to present at the Global Cardio Oncology Summit in the U.S. later this year, reflecting industry interest in the trial.

Investors also raised questions about Racura Oncology's media strategy, with several executive appearances during the week drawing attention and prompting further discussion on the forum.

The original article stated that its material was provided for information only and should not be treated as investment advice. It also encouraged viewers to conduct their own research and consult a certified financial adviser before making investment decisions.